Subsequently, targeting H19, telomerase, and specific miRNAs, such as miR-let-7a, offers promising avenues for the treatment of BC by disrupting key processes involved in tumor progression and metastasis, which can enhance therapeutic efficacy, overcome resistance, and improve patient outcomes in a personalized manner. Here, H19 is linked to neoplasm.